IPHA — Innate Pharma SA Share News
0.000.00%
Last trade - 00:00- $172.79m
- $159.33m
- €2.79m
Brief: Innate Pharma Announces Positive Data From Phase 2 Trial For Lacutamab
French and Benelux stocks-Factors to watch
Innate Pharma falls on FDA's partial hold on cancer drug trial
Brief: Innate Pharma Provides Update On Lacutamab Clinical Programme
Brief: Innate Pharma Announces Presentation Of Interim Results Of Phase 2 Tellomak Study With Lacutamab
Brief: Innate Pharma Posts H1 Net Income Of EUR 1.7 Mln
Brief: Sanofi Makes Milestone Payment To Innate Pharma After Start of SAR'514/IPH6401 Clinical Trial
Brief: Innate Pharma SA - First Patient Dosed In Phase 2 Matisse Trial Of Iph5201 In Early Stage Lung Cancer
Brief: Innate Pharma: 1st Patient Dosed In Phase 2 Matisse Trial Of IPH5201 In Early Stage Lung Cancer
Brief: Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results Of Phase 2 Tellomak Study With Updated Olsen Criteria
Brief: Innate Pharma To Present Updated Interim Phase 2 Efficacy Results Of Lacutamab In Mycosis Fungoides
Brief: Innate Pharma: FDA Grants Fast Track Designation For SAR'579 / IPH6101 For Treatment Of Hematological Malignancies
Brief: Innate Pharma Updates On SAR'579/IPH6101 In R/R Aml
Brief: Innate Pharma To Present IPH6501 Preclinical Data At The EHA 2023 Congress
Brief: Innate Pharma Q1 Revenue Up At EUR 26.0 Million
Innate Pharma jumps after license deal with Takeda
Brief: Innate Pharma Announces Exclusive Antibody License To Takeda
Brief: Innate Pharma End-2022 Cash Position Of EUR 136.6 Million
Brief: Innate Pharma Says Has No Financial Exposure To Silicon Valley Bank